Phase I Study to Evaluate the Safety of Cellular Immunotherapy for Recurrent/Refractory Neuroblastoma Using Genetically-Modified Autologous CD8+ T Cell Clones
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Aldesleukin; Antineoplastics; Gene therapies
- Indications Neuroblastoma
- Focus Therapeutic Use
- 21 Sep 2010 Biomarkers information updated
- 17 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Sep 2010 Actual end date (Mar 2005) added as reported by ClinicalTrials.gov.